---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-170888"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2026-04-23T23:59:59+00:00"
generated_at: "2026-05-15T04:38:04.346798+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BBOT appoints Pedro Beltran as CEO, Idan Elmelech as COO, and Neil Kumar as Executive Chairman

## Summary
- Pedro Beltran, previously CSO, succeeds Eli Wallace as President and CEO effective April 20, 2026; also named Class III director.
- Idan Elmelech, former SVP Strategy, promoted to COO, principal financial officer; Marc Cobo becomes principal accounting officer.
- CFO Uneek Mehra departs April 30, 2026; no disagreement cited.
- Neil Kumar appointed Executive Chairman; founder figure to guide next development phase.
- Eli Wallace transitions to Senior Adviser; Board thanks him for service.

## SEC filing metadata
- accession: 0001193125-26-170888
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2026-04-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000119312526170888/0001193125-26-170888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000119312526170888/d253464d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-170888
- JSON: https://secwatch.observer/filing/0001193125-26-170888.json
- Plain text: https://secwatch.observer/filing/0001193125-26-170888.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.